Home » Janssen Creates Division to Launch TMC435 and Help Conquer Hep C in EMEA
Janssen Creates Division to Launch TMC435 and Help Conquer Hep C in EMEA
Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceuticals, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
07May
-
14May
-
30May